PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDoxorubicin
Doxorubicin hydrochloride, Caelyx pegylated liposomal(doxorubicin)
Doxil, Doxorubicin, Myocet, Pegylated (doxorubicin) is a small molecule pharmaceutical. Doxorubicin was first approved as Doxorubicin hydrochloride on 1982-01-01. It is used to treat breast neoplasms, gastrointestinal neoplasms, hodgkin disease, lung neoplasms, and myeloid leukemia acute amongst others in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, multiple myeloma, and ovarian neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Show 1 more
Trade Name
FDA
EMA
Doxil, Doxorubicin (discontinued: Adriamycin, Doxorubicin, Rubex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Doxorubicin hydrochloride
Tradename
Company
Number
Date
Products
DOXIL (LIPOSOMAL)BaxterN-050718 RX1995-11-17
2 products, RLD
DOXORUBICIN HYDROCHLORIDEPfizerN-050629 RX1987-12-23
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
adriamycinANDA2024-04-11
doxilNew Drug Application2026-03-10
doxorubicin hydrochlorideANDA2026-08-31
doxorubicin hydrochloride liposomeANDA2026-02-24
doxorubicin hydrochloride, liposomalunapproved drug for use in drug shortage2023-12-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia acute—D015470C92.0
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
thyroid neoplasmsEFO_0003841D013964—
gastrointestinal neoplasms—D005770C26.9
lung neoplasms—D008175C34.90
neuroblastomaEFO_0000621D009447—
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
urinary bladder neoplasms—D001749C67
osteosarcoma—D012516—
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DB: Anthracyclines and related substances
— L01DB01: Doxorubicin
HCPCS
Code
Description
J9000
Injection, doxorubicin hydrochloride, 10 mg
Q2049
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Clinical
Clinical Trials
3113 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—14——4
NeutropeniaD009503—D70—12——2
Chemotherapy-induced febrile neutropeniaD064146———12——2
LymphomaD008223—C85.9—11——2
Mucinous adenocarcinomaD002288———12——2
Ductal carcinoma breastD018270———12——2
Inflammatory breast neoplasmsD058922———12——2
Non-hodgkin lymphomaD008228—C85.9——1——1
Mantle-cell lymphomaD020522—C83.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD016393———1———1
NeoplasmsD009369—C80—1———1
Hodgkin diseaseD006689—C81—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDoxorubicin
INNdoxorubicin
Description
Doxorubicin is a deoxy hexoside, an anthracycline, an anthracycline antibiotic, an aminoglycoside, a member of tetracenequinones, a member of p-quinones, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It has a role as an Escherichia coli metabolite. It is a conjugate base of a doxorubicin(1+). It derives from a hydride of a tetracene.
Classification
Small molecule
Drug classantineoplastic antibiotics (daunorubicin type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Identifiers
PDB—
CAS-ID23214-92-8
RxCUI—
ChEMBL IDCHEMBL53463
ChEBI ID28748
PubChem CID31703
DrugBankDB00997
UNII ID80168379AG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Doxorubicin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 129,848 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adriamycin, Doxil, Doxorubicin hydrochloride, Doxorubicin hydrochloride liposome
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
118,972 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use